Health
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class ther
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"Ovid Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ovid Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/27DLXferaeZxhRE9vCTuYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142}},"lazy":false},{"type":"text","content":"NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance.","length":576,"tagName":"p"},{"type":"text","content":"Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives began from her early career as a practicing neurologist who treated patients with refractory and treatment-resistant epilepsies and neuromuscular disorders. She has held leadership roles in biopharmaceutical companies and at the National Institutes of Health, where she directed national rare-disease research and clinical-trial infrastructure. Her background includes patient-focused trial design informed by cutting-edge biomarker strategies and quantitative clinical planning. She is a proven drug developer who will help guide the advancement of Ovid’s next-generation GABA-AT inhibitor, OV329, and the Company’s broad portfolio of first-in-class KCC2 direct activators.","length":870,"tagName":"p"},{"type":"text","content":"“Petra brings a compelling combination of creative drug development, regulatory experience and the deep care of a physician who has treated people suffering from complex neurological conditions,” said Meg Alexander, President and Chief Operating Officer of Ovid Therapeutics. ...